Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population
When oxidative stress occurs, red blood cells often rupture, leading to hemolytic anemia
albicans to construct mcp1 -/- strain [15]
Clinical Diabetes : A Publication of the American Diabetes Association, 37 (3), 227233
Peter Lurie, a former FDA official who now leads the Center for Science in the Public Interest
While additional research must be conducted to prove causation, this study demonstrates that muscle preservation during GLP-1 treatment is achievable